Mirum Pharmaceuticals promotes Peter Radovich to President effective Jan 16, 2024

Mirum Pharmaceuticals, Inc.

Peter Radovich promoted to President, effective Jan 16, 2024, while continuing as COO.
Christopher Peetz remains CEO; Radovich had served as COO since April 2020.
Radovich previously held senior roles at Global Blood Therapeutics and Onyx Pharmaceuticals.
Promotion expands Radovich's responsibilities but no change in CEO role.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Peter Radovich

President

MIRM · Mirum Pharmaceuticals, Inc.

Effective: 2024-01-16
Filed: January 16, 2024, 6:59 PM ET

On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.

Role change

Christopher Peetz

Chief Executive Officer

MIRM · Mirum Pharmaceuticals, Inc.

Effective: 2024-01-16
Successor: Peter Radovich
Filed: January 16, 2024, 6:59 PM ET

On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Radovich changed role as President at Mirum Pharmaceuticals, Inc..

Action: promoted
Role: President

Exact text from the filing

On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Peetz changed role as Chief Executive Officer at Mirum Pharmaceuticals, Inc..

Role: Chief Executive Officer

Exact text from the filing

On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.

View on SEC.gov

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-008569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.